J Virol 2012, 86:3916–3923.EX527 PubMedCrossRef 13. Wang L, Damania B: Kaposi’s sarcoma-associated herpesvirus selleck inhibitor confers a survival advantage to endothelial cells. Cancer Res 2008, 68:4640–4648.PubMedCrossRef 14. Bhatt AP, Damania B: AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV. Front Immunol 2012, 3:401.PubMed

15. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004, 30:193–204.PubMedCrossRef 16. Ward PS, Thompson CB: Signaling in control of cell growth and metabolism. Cold Spring Harb Perspect Biol 2012, 4:a006783.PubMedCrossRef 17. Shi Y, Paluch BE, Wang X, Jiang X: PTEN at a glance. J Cell Sci 2012, 125:4687–4692.PubMedCrossRef 18. Pal I, Mandal M: PI3K And Akt as molecular targets for cancer therapy: current clinical outcomes. Acta Pharmacol Sin 2012, 33:1441–1458.PubMedCrossRef 19. Datta SR, Brunet A, Greenberg ME: Cellular survival: a play in three akts. Genes Dev 1999, 13:2905–2927.PubMedCrossRef 20. Tomlinson CC, Damania B: The K1 protein of Kaposi’s sarcoma-associated

herpesvirus activates the Akt signaling pathway. J Virol 2004, 78:1918–1927.PubMedCrossRef 21. Sodhi A, Montaner S, Patel V, Gomez-Roman JJ, Li Y, Sausville EA, Sawai ET, Gutkind JS: Akt plays a central role in sarcomagenesis induced by Kaposi’s sarcoma herpesvirus-encoded AC220 G protein-coupled receptor. Proc Natl Acad Sci USA 2004, 101:4821–4826.PubMedCrossRef 22. Garufi A, Ricci A, Trisciuoglio D, Iorio E, Carpinelli G, Pistritto G, Cirone M, D’Orazi G: Glucose restriction induces cell death in parental but not in homeodomain-interacting protein kinase 2-depleted RKO colon cancer cells: molecular mechanisms and implications

for tumor therapy. Cell Death Dis 2013, 4:e639.PubMedCrossRef 23. Munoz-Pinedo C, El Mjiyad N, Ricci JE: Cancer metabolism: current perspectives and future directions. Cell Death Dis 2012, 3:e248.PubMedCrossRef filipin 24. Ward PS, Thompson CB: Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 2012, 21:297–308.PubMedCrossRef 25. Tseng LM, Liu CY, Chang KC, Chu PY, Shiau CW, Chen KF: CIP2A is a target of bortezomib in human triple negative breast cancer cells. Breast Cancer Res 2012, 14:R68.PubMedCrossRef 26. Liu CY, Shiau CW, Kuo HY, Huang HP, Chen MH, Tzeng CH, Chen KF: Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells. Haematol 2013, 98:729–738.CrossRef 27. Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, Cheng AL: Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res 2008, 68:6698–6707.PubMedCrossRef 28. Zhang XD, Deslandes E, Villedieu M, Poulain L, Duval M, Gauduchon P, Schwartz L, Icard P: Effect of 2-deoxy-D-glucose on various malignant cell lines in vitro. Anticancer Res 2006, 26:3561–3566.PubMed 29.